177 related articles for article (PubMed ID: 37146405)
21. Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma.
Coppola D; Fu L; Nicosia SV; Kounelis S; Jones M
Hum Pathol; 1998 May; 29(5):455-62. PubMed ID: 9596268
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.
Cheng CW; Wang HW; Chang CW; Chu HW; Chen CY; Yu JC; Chao JI; Liu HF; Ding SL; Shen CY
Breast Cancer Res Treat; 2012 Aug; 134(3):1081-93. PubMed ID: 22476851
[TBL] [Abstract][Full Text] [Related]
23. p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study.
Abdelrahman AE; Salem A; Al Attar AZ; Elsebai E; Samy W; Ibrahim MA; Ibrahim HM
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):713-725. PubMed ID: 36251972
[TBL] [Abstract][Full Text] [Related]
24. RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma.
Liu S; Lin M; Ji H; Ding J; Zhu J; Ma R; Meng F
Diagn Pathol; 2019 Jan; 14(1):7. PubMed ID: 30684972
[TBL] [Abstract][Full Text] [Related]
25. Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools.
Besso MJ; Montivero L; Lacunza E; Argibay MC; Abba M; Furlong LI; Colas E; Gil-Moreno A; Reventos J; Bello R; Vazquez-Levin MH
Oncol Rep; 2020 Sep; 44(3):873-886. PubMed ID: 32705231
[TBL] [Abstract][Full Text] [Related]
26. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
27. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
[TBL] [Abstract][Full Text] [Related]
28. The role of WWOX tumor suppressor gene in the regulation of EMT process via regulation of CDH1-ZEB1-VIM expression in endometrial cancer.
Płuciennik E; Nowakowska M; Pospiech K; Stępień A; Wołkowicz M; Gałdyszyńska M; Popęda M; Wójcik-Krowiranda K; Bieńkiewicz A; Bednarek AK
Int J Oncol; 2015; 46(6):2639-48. PubMed ID: 25892250
[TBL] [Abstract][Full Text] [Related]
29. Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?
Liao CL; Hsu JD; Lee MY; Kok LF; Li YJ; Wang PH; Yao CC; Han CP
Virchows Arch; 2010 Apr; 456(4):377-86. PubMed ID: 20221633
[TBL] [Abstract][Full Text] [Related]
30. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.
Tomica D; Ramić S; Danolić D; Šušnjar L; Perić-Balja M; Puljiz M
J Obstet Gynaecol; 2018 Jan; 38(1):96-102. PubMed ID: 28764605
[TBL] [Abstract][Full Text] [Related]
31. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract][Full Text] [Related]
32. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
[TBL] [Abstract][Full Text] [Related]
33. [Coexpression of MAP2K4 and vimentin proteins in human endometrial carcinoma and its clinicopathological significance].
Liu CH; Jiang QP; Lin D; Chen W; Xiao YY; Lin L; Deng YR; Jiang HP; Guo SQ
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Feb; 37(2):157-164. PubMed ID: 28219857
[TBL] [Abstract][Full Text] [Related]
34. Value of T cell receptor gamma alternate reading frame protein and keratin 5 in endometrial carcinoma.
Zhao LJ; Li XP; Qi WJ; Wang JL; Wei LH
Chin Med J (Engl); 2013 Nov; 126(22):4260-4. PubMed ID: 24238509
[TBL] [Abstract][Full Text] [Related]
35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
36. L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.
Klat J; Mladenka A; Dvorackova J; Bajsova S; Simetka O
Anticancer Res; 2019 Jan; 39(1):421-424. PubMed ID: 30591489
[TBL] [Abstract][Full Text] [Related]
37. TRP channel expression correlates with the epithelial-mesenchymal transition and high-risk endometrial carcinoma.
Van den Eynde C; De Clercq K; Van Bree R; Luyten K; Annibali D; Amant F; Han S; Van Nieuwenhuysen E; Baert T; Peeraer K; Voets T; Van Gorp T; Vriens J
Cell Mol Life Sci; 2021 Dec; 79(1):26. PubMed ID: 34936030
[TBL] [Abstract][Full Text] [Related]
38. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.
Bignotti E; Ragnoli M; Zanotti L; Calza S; Falchetti M; Lonardi S; Bergamelli S; Bandiera E; Tassi RA; Romani C; Todeschini P; Odicino FE; Facchetti F; Pecorelli S; Ravaggi A
Br J Cancer; 2011 Apr; 104(9):1418-25. PubMed ID: 21468050
[TBL] [Abstract][Full Text] [Related]
40. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
